Efficacy and Safety Study of Prolonged-Release Fampridine in Subjects With Multiple Sclerosis (ENHANCE)

The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on patient-reported walking ability over a 24-week study period.

The secondary objectives are to determine whether prolonged-release fampridine 10 mg taken twice daily (BID) has a clinically meaningful effect on dynamic and static balance, physical impact of MS, and upper extremity function over a 24-week study period, to evaluate criteria for early assessment of response to fampridine that can predict clinically meaningful benefits in walking ability and balance and assess the safety and tolerability of prolonged-release fampridine 10 mg twice daily over a 24-week treatment period.